The dysregulation of biomolecular condensates explains the root cause of complex diseases and paves the way to novel therapies
Watch video
Translating condensate biology into medicine
We have assembled the most extraordinary talent in condensate science, drug discovery and data science, emerging as the world’s leading condensate biotechnology company
Our Chief Scientific Officer, Isaac Klein, reviews the astonishing progress that we have made over the past 5 years towards drugging biomolecular condensates to address diseases of high unmet need.
The collaboration aims to explore the field of biomolecular condensates to treat insulin resistance and diabetes progression.
A daring vision
There are times when a discovery is made, and its importance is astounding. The discovery of biomolecular condensates is a revelation so profound it completely transforms the understanding of cellular function and organization.
We have advanced this new foundational principle of cell biology to shape a daring vision - that the dysregulation of biomolecular condensates explains the root cause of complex diseases and paves the way to novel therapies[...]
To lead the way in the discovery of transformative condensate modulating therapies, Dewpoint has developed a fully integrated suite of technologies.
We combine expertise from complementary state-of-the-art experimental technologies with a powerful AI platform to develop powerful therapies across a broad range of therapeutic areas, including some of the most devastating diseases.
Our teams feel inspired, valued and included, and we have a lot of fun along the way. Dewpoint is a place to show up as your authentic self and make an impact.
We’re re-defining what the very spirit of company culture can be. We call ourselves the D.team and together we’ve built a unique place to work.